Entity

Time filter

Source Type


Li Y.,Chinese Peoples Armed Police forces Academy | Liang Y.,Chinese Peoples Armed Police forces Academy | Liu Y.,Institute of Liver Transplantation
Journal of Chinese Mass Spectrometry Society | Year: 2015

The mass spectrometry method was established for analysis of differentially expressed protein in human serum after liver transplantation with immunosuppressive agent. The proteins in serum before and after liver transplantation were separated by two-dimensional gel electrophoresis with silver staining, the differentially expressed proteins on the gel were digested with surfactant Rapigest SF and trypsin and then identified by nanoUPLC-ESI-MS/MS. In the experiment, 9 differentially expressed protein spots were identified clearly, corresponding to 8 different proteins. It was found that differentially expressed proteins are mostly related to immune regulation and liver disease, and it may provide clues for the in-depth study the anti-rejection effect of immunosuppressive agent after liver transplantation. ©, 2015, Chinese Society for Mass Spectrometry. All right reserved. Source


Zhu Y.,Beijing Jiaotong University | Zhu Y.,Tumor Center in Beijing 301 Hospital | Feng F.,Beijing Institute of Pharmacology and Toxicology | Yu J.,Beijing Institute of Basic Medicine Science | And 5 more authors.
DNA and Cell Biology | Year: 2013

Long interspersed nucleotide element (LINE-1; L1) as an autonomous retrotransposon is localized usually in AT-rich, low-recombined, and gene-poor regions of genome. It is transiently activated in embryonic development and continuously activated in all tumor cells tested so far. Full-length L1 gene contains 5′ untranslated region, two open reading frames (ORFs) encoded L1ORF1p and L1ORF2p, and a 3′ terminal polyadenylation site. Compared with L1ORF2p, a protein encompassing reverse transcriptase and endonuclease activities, L1ORF1p remains to be elucidated. With liver cancer cells and tissues, the expression and sub-localization of L1ORF1p were investigated and shown that L1-ORF1p expresses just in liver cancer cells and tissues but not in normal liver cells and almost not in adjacent tissues. To characterize L1ORF1p, the strategies for over-expression and down-regulation of L1ORF1p in transfected cells were implemented. The phenomenon of promoting cell proliferation and colony formation was observed in transfected cells with L1ORF1p over-expression and vice versa. Down-regulation of L1ORF1p suppresses tumorigenesis in vitro and in vivo. Smad4 as an interaction protein of L1ORF1p is identified for the first time, while L1ORF1p is responsible for Smad4 sequestration in the cytoplasm. Thus, L1ORF1p contributed to tumorigenesis and may attribute to, at least partly, its participation in Smad4-signaling regulation. © Mary Ann Liebert, Inc. Source


Zhang Q.,Institute of Liver Transplantation | Chen X.,Institute of Liver Transplantation | Zang Y.,Institute of Liver Transplantation | Zhang L.,Shaanxi Provincial Corps Hospital of Chinese Peoples Armed Police Force | And 6 more authors.
PLoS ONE | Year: 2012

Background: A precise predictive survival model of liver transplantation (LT) with antiviral prophylaxis for hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) and cirrhosis has not been established. The aim of our study was to identify predictors of outcome after LT in these patients based on tumor staging systems, antitumor therapy pre-LT, and antiviral prophylaxis in patients considered to be unfit by Milan or UCSF criteria. Methods: From 2002 to 2008, 917 LTs with antiviral prophylaxis were performed on patients with HBV-cirrhosis, and 313 had concurrent HCC. Results: Stratified univariate and multivariate analyses demonstrated that independent predictors for poor survival were tumor size >7.5 cm (P = 0.001), tumor number >1 (P = 0.005), vascular invasion (P = 0.001), pre-LT serum alpha-fetoprotein (AFP) level ≥1000 ng/ml (P = 0.009), and pre-LT aspartate aminotransferase (AST) level ≥120 IU/L (P = 0.044). Pre-LT therapy for HCC was an independent predictor of better survival (P = 0.028). Based on CLIP and TNM tumor staging systems, HCC patients with HBV-cirrhosis who met the following criteria: solitary tumor ≤7.5 cm, or ≤4 multifocal nodules, the largest lesion ≤5 cm and total tumor diameter ≤10 cm, or more nodules with the largest lesion ≤3 cm, and pre-LT serum AFP level <1000 μg/L and AST level <120 IU/L without vascular invasion and lymph node metastasis who were unfit for UCSF, had survival rates of 89% at 5 years. There was a 47% 5-year survival rate for patients with HCC exceeding the revised criteria. Conclusions: The current criteria for LT based on tumor size, number and levels of AFP and AST may be modestly expanded while still preserving excellent survival after LT. The expanded criteria combined with antiviral prophylaxis and pre-LT adjuvant therapy for HCC may be a rational strategy to prolong survival after LT for HCC patients with HBV-associated cirrhosis. © 2012 Zhang et al. Source


Zhang Q.,Institute of Liver Transplantation | Chen H.,Institute of Liver Transplantation | Li Q.,Shaanxi Carcinoma Hospital | Zang Y.,Institute of Liver Transplantation | And 4 more authors.
Investigational New Drugs | Year: 2011

The purpose of this study was to evaluate the efficacy of postoperative adjuvant chemotherapy with FOLFOX regimen on the outcome after LT for HCC patients who did not meet the Milan criteria. Ninety-five consecutive HCC patients with liver cirrhosis undergoing LT were enrolled. Fifty-eight who did not meet the Milan criteria were randomized to open-label treatment with or without adjuvant chemotherapy after LT (n=29/group). The FOLFOX chemotherapy protocol comprised 3-week cycles of oxaliplatin 100 mg/m 2 on day 1, leucovorin (calcium folinate, CF) 200 mg/m 2 on day 1 followed by 3-day, and 5-fluorouracil (5-FU) 2000 mg/m 2 as a 48-h continuous infusion, for up to six courses in the 1st year after transplantation. Median survival was extended by 4.57months by combination chemotherapy. The 1-and 3-year survival rates were 89.7% and 79.3% with chemotherapy versus69.0% and 62.1% without chemotherapy. The cumulative 1-year survival was significantly increased by chemotherapy (log-rank test, P=0.043). The 6-month tumor-free survival rate was 24.1% higher with chemotherapy than without. The recurrence rate after LT was significantly different between the two groups at 6 months (P=0.036), but not at 3 years (P=0.102). The chemotherapy regimen was generally well tolerated. Post-LTadjuvant chemotherapy with oxaliplatin/5-FU/CF could not prevent tumor recurrence post-LT but may contribute to improve the survival of HCC patients who do not meet the Milan criteria. These results should be verified in a larger sample with a longer follow-up period. © Springer Science+Business Media, LLC 2010. Source


Zhang Q.,Institute of Liver Transplantation | Hao Y.-W.,Computer Management Center | Yue Y.,Institute of Liver Transplantation | Chen H.,Institute of Liver Transplantation | And 3 more authors.
Chinese Journal of Tissue Engineering Research | Year: 2014

BACKGROUND: The establishment of a standardized clinical liver transplantation specimen bank is the primary condition for scientific research in this field, which can help to provide a qualified sample resource platform for research. OBJECTIVE: To primarily establish biological specimen bank of hepatocellular carcinoma for liver transplantation, to explore the standardized procedures of specimen collection, processing and preservation of hepatocellular carcinoma for liver transplantation, and to establish the sound and comprehensive information management system of clinical information of collected specimens. METHODS: In accordance with standardized procedures to establish biological specimen banks, the operational processes and quality control system were formulated. Liver tissue and blood samples of hepatocellular carcinoma recipients undergoing liver transplantation were regularly collected, managed and stored. Simultaneously, liver tissue and blood samples of benign liver disease in liver transplant recipients and of healthy donor were collected as controls. A systematic management was conducted in collected specimens and corresponding clinical information. RESULTS AND CONCLUSION: From August 2009, tissue and blood samples of 501 cases of receipts and donors undergoing liver transplantation with complete clinical information were collected from the specimen bank, including 203 hepatocellular carcinoma specimens, 214 benign liver disease specimens and 84 healthy donor specimens. These specimens included tumor tissue, adjacent tissues and distal non-cancerous tissue specimens, totally 1 773. A total of 45 specimens were randomly selected for quality monitoring. The collected specimens had a high quality. Specimen information data computer management system was developed. This study initially established a standardized research-based clinical transplantation specimen bank, which is helpful to elevate sample quality and has a good manipuility. © 2014, Journal of Clinical Rehabilitative Tissue Engineering Research. All rights reserved. Source

Discover hidden collaborations